Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Endocrine 1Dermatologic 1CNS 1

Conditions

Neoplasms 2Vipoma 1Uveal Melanoma 1Somatostatinoma 1Small Cell Lung Carcinoma 1Pheochromocytoma 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Insulinoma 1Head and Neck Neoplasms 1Glucagonoma 1Gastrinoma 1Esthesioneuroblastoma, Olfactory 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

Cyclophosphamide 9fludarabine 8Interleukin-2 8aldesleukin 7Sunitinib 6Everolimus 6Bevacizumab 6fludarabine phosphate 5Sorafenib 5Radiotherapy 4Nivolumab 4Gene Expression Profiling 4Filgrastim 4pembrolizumab 3peginterferon alfa-2b 3Stem Cell Transplantation 3Radiotherapy, Intensity-Modulated 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Immunohistochemistry 3Granulocyte Colony-Stimulating Factor 3cabozantinib 2atezolizumab 2Thiotepa 2Sodium Chloride 2Reverse Transcriptase Polymerase Chain Reaction 2Polymerase Chain Reaction 2Mycophenolic Acid 2Mesna 2Immunoenzyme Techniques 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Kidney Neoplasms × pentetreotide × Clear all
NCT00002947 2014-07-02

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

Yale University

Phase 1 Terminated
35 enrolled
CNSDermatologicEndocrineGenitourinaryHead & NeckThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Vipoma, Glucagonoma, Head and Neck Neoplasms, Insulinoma, Adenoma, Islet Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Pheochromocytoma, Somatostatinoma, Carcinoma, Merkel Cell, Gastrinoma, Central Nervous System Neoplasms, Carcinoma, Islet Cell, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡